Safety and Preliminary Efficacy of BNT314 with or Without an Immune Checkpoint Inhibitor in Cancer Patients with Malignant Solid Tumors
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- Registration Number
- NCT06150183
- Lead Sponsor
- BioNTech SE
- Brief Summary
The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone and when it is used together with another antibody cancer drug (pembrolizumab) in patients with different types of cancer. Patients will receive either BNT314 alone or BNT314 combined with pembrolizumab.
Phase 1 of the study consists of a dose escalation part, and a safety run-in (SRI) and expansion part:
Dose escalation: In this part of the study, patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose (MTD) which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose (MAD) will be investigated. At the end of this part, the Recommended Phase 2 Dose (RP2D) which is the dose to be tested in Phase 2 will be decided.
Safety Run-In: In this part of the study, BNT314 will be combined with pembrolizumab. Before starting the expansion part, the combination will be tested in another small group of participants (12-28) to find out how safe this combination is.
Expansion: In this part of the study, BNT314 will be combined with pembrolizumab. After the SRI is completed, the study will continue with the expansion part where up to 199 participants with different types of cancer will be included.
The Phase 2 part of the study will be introduced via an amendment to the study protocol.
- Detailed Description
This is a multicenter, multinational safety study in patients with metastatic or advanced malignant solid tumors for whom, at the discretion of the investigator, there is no available standard therapy likely to confer clinical benefit, evaluating the safety, tolerability, preliminary antitumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of BNT314.
In the dose escalation part of the study, patients will periodically receive one infusion of BNT314. In the combination therapy SRI and expansion part, BNT314 will be combined with pembrolizumab and administered intravenously in periodic cycles to patients with selected cancer indications.
Additional cohorts (backfill cohorts) administering BNT314 as monotherapy will assign patients to specific DLs, based on the emerging safety, PK, and pharmacodynamic data. This would allow for further assessment of dose- and exposure-response relationships for clinical activity, safety, and tolerability to support BNT314 dose optimization.
The treatment period will last until progressive disease (PD), confirmed PD (as per immune response evaluation criteria in solid tumors \[iRECIST\]), unacceptable toxicity, or withdrawal of consent, whichever happens first.
For the combination therapy, the maximum treatment period will be 2 years. The maximum study duration is 3 years after the last participant's first treatment in the study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 360
-
Have the ability to voluntarily give informed consent by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.
-
Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, and other requirements of the study. This includes that they are able to understand and follow study-related instructions.
-
Are ≥18 years of age at the time of giving informed consent.
-
Have measurable disease according to RECIST v1.1.
-
Have a life expectancy of >3 months.
-
Have Eastern Cooperative Oncology Group Performance Status score of 0 or 1 at screening.
-
Have adequate coagulation function at screening as determined by:
- International normalized ratio or prothrombin time ≤1.5 × upper limit normal (ULN; unless on therapeutic anticoagulants with values within therapeutic window).
- Activated partial thromboplastin time ≤1.5 × ULN (unless on therapeutic anticoagulants with values within therapeutic window).
-
Have adequate bone marrow/hematologic function at screening as determined by:
- Absolute neutrophil count (ANC) ≥1.5 × 10^9/L (≥1500/μL) (patients may not use granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor to achieve these ANC levels in the past 7 days).
- Platelet count ≥100 × 10^9/L (≥100,000/μL).
- Hemoglobin ≥9 g/dL.
- Any blood transfusions ≤28 days before first dose of study treatment should be documented.
-
Have adequate hepatic function at screening as determined by:
- Total bilirubin (Tbili) ≤1.5 × ULN OR direct bilirubin ≤ULN for patients with Tbili levels >1.5 × ULN. Exception for patients in monotherapy: Patients with Gilbert's syndrome must have a Tbili <3 mg/dL and direct bilirubin ≤ULN.
- Alanine aminotransferase and aspartate aminotransferase ≤2.5 ULN for patients with or without liver metastases.
- Albumin ≥30 g/L.
-
Have adequate renal function at screening as determined by glomerular filtration rate ≥45 mL/min/1.73 m^2 according to the abbreviated Modification of Diet in Renal Disease equation.
-
Have adequate pancreas function at screening as determined by serum amylase and lipase with no signs and symptoms of pancreatitis.
-
Patients of childbearing potential (POCBP) must have a negative urine and serum beta human chorionic gonadotropin test at screening. Patients that are postmenopausal or permanently sterilized (verified by medical records) will not be considered POCBP, and therefore are not required to undergo pregnancy testing.
-
POCBP must agree to practice a highly effective form of contraception and to require their male partners to use condoms with a spermicidal agent, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
-
POCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
-
Males who are sexually active and have not had a bilateral vasectomy or orchidectomy must agree to use condoms with a spermicidal agent and to require their female partners to practice a highly effective form of contraception during the study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
-
Males must be willing to refrain from sperm donation, starting at Visit D1 and thereafter until 120 days (one sperm cycle) after receiving the last study treatment.
-
Patients must have a histologically confirmed advanced malignant solid tumor, having experienced disease progression on or after standard therapy, or were intolerant of or not eligible for standard therapy (only for the monotherapy dose escalation part).
Inclusion criteria specific to selected tumor indications may apply only for the combination therapy SRI and dose expansion parts of the study.
-
Patients that have uncontrolled intercurrent illness, including but not limited to:
- Ongoing or active infection requiring treatment with anti-infective therapy administered less than two weeks prior to first dose.
- Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris, or symptomatic untreated cardiac arrhythmia. Treated and/or asymptomatic cardiac arrythmia/atrial fibrillation will be allowed.
- History of arterial thrombosis or pulmonary embolism within 6 months before the first dose of study treatment.
- History of myocardial infarction within 6 months before the first dose of study treatment.
- Uncontrolled hypertension defined as systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg, despite optimal medical management.
- Prolonged QTc interval at baseline of ≥470 milliseconds using Fridericia's QT correction formula.
- Ongoing or recent (within one year of screening) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events (irAEs).
- History of Grade 3 or higher irAEs that led to treatment discontinuation of a checkpoint inhibitor. A patient with irAEs below Grade 3 that led to discontinuation should be discussed with the sponsor. Grade 3 irAEs that have fully recovered may also be discussed.
- History of chronic liver disease (e.g., alcoholic hepatitis or nonalcoholic steatohepatitis, drug-related or autoimmune hepatitis) or evidence of hepatic cirrhosis.
- History of non-treated intracerebral arteriovenous malformation (shunts), non-treated cerebral aneurysm, spinal cord compression (from disease), carcinomatous meningitis, or stroke will be excluded.
- History of acute or chronic pancreatitis of any etiology within 6 weeks prior to the start of study treatment.
- Evidence of interstitial lung disease.
- Ongoing pneumonitis or history of noninfectious pneumonitis that has required steroids.
- Transient ischemic attack less than one month prior to screening will be excluded.
- History of brain/central nervous system (CNS) metastases. Patients with newly identified or known unstable or symptomatic CNS metastases will be excluded. Patients with previously treated brain metastases are allowed provided lesions are radiologically stable (i.e., without evidence of progression) for at least 28 days by repeat imaging, latest imaging performed maximum 6 weeks prior to Cycle 1, Day 1.
- Serious, non-healing wound, skin ulcer (of any grade), or bone fracture will be excluded.
- Other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate patient participation in this clinical study (e.g., acute or chronic pancreatitis, active hepatitis). Known primary immunodeficiencies, either cellular (e.g., DiGeorge syndrome, T-cell negative severe combined immunodeficiency [SCID] or combined T- and B-cell immunodeficiencies (e.g., T- and B-cell negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).
- Major surgery within 3 weeks before signature of the ICF unless fully recovered from the surgery in the opinion of the investigator.
-
Prior therapy:
- Radiotherapy within 14 days prior to first BNT314 administration. Palliative radiotherapy will be allowed, but not to target lesions.
- Any epithelial cell adhesion molecule- or 4-1BB-targeting treatment.
- Treatment with an anticancer agent within 4 weeks or for systemic therapies after at least five half-lives of the drug, whichever is shorter, prior to study treatment administration.
- Patient has received any investigational agent (including investigational vaccines) or used an invasive investigational medical device within 28 days before the planned first dose of BNT314 or is currently enrolled in an interventional study. Patients who are in the follow-up phase of an interventional study may participate if they have not received an investigational agent within 28 days (or five half-lives, whichever is longer) of the first dose of BNT314.
- Patient has a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of the first dose of BNT314. Inhaled or topical steroids, and adrenal or pituitary replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- Patient has received granulocyte or granulocyte/macrophage colony stimulating factor (G-CSF/GM-CSF) support within 2 weeks prior to first BNT314 administration or is chronically transfusion dependent; G-CSF and other hematopoietic factors may be used in the management of acute toxicity (such as febrile neutropenia) or prophylactically, when clinically indicated at the investigator's discretion.
- Received any live vaccine within 30 days prior to the start of study treatment.
-
Any positive test for hepatitis B (defined as positive for hepatitis B surface antigen or hepatitis B virus DNA), indicating acute or chronic infection.
-
Any positive test for hepatitis C (defined as positive for hepatitis C virus antibody or hepatitis C virus RNA), indicating acute or chronic infection.
-
Known alcohol dependency within 6 months enrollment in this study.
-
Planned enrollment in another study of an IMP, starting after Visit D1 and continuously until the last planned visit in this study.
-
Have a medical, psychological, or social condition which, in the opinion of the investigator, could compromise their wellbeing if they participate in the study, or that could prevent, limit, or confound the protocol specified assessments or procedures, or that could impact adherence to protocol-described requirements.
-
Are subject to exclusion periods from another investigational study.
-
Are vulnerable individuals as per International Council for Harmonisation E6 definition, i.e., are individuals whose willingness to participate in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description BNT314 Monotherapy BNT314 Escalating dose levels and backfill cohorts BNT314 + pembrolizumab BNT314 The BNT314 starting dose for the SRI combination therapy will be one DL lower than the RP2D/MTD/maximum administered dose (MAD) determined from the monotherapy dose escalation. BNT314 + pembrolizumab Pembrolizumab The BNT314 starting dose for the SRI combination therapy will be one DL lower than the RP2D/MTD/maximum administered dose (MAD) determined from the monotherapy dose escalation.
- Primary Outcome Measures
Name Time Method Monotherapy - Dose escalation and backfill cohorts. Number and proportion of patients with occurrence of Grade ≥ 3 abnormal safety laboratory parameters from first dose of study treatment to 90 days after last dose of study treatment Monotherapy - Dose escalation. Occurrence of dose-limiting toxicity (DLTs) within a cohort during the DLT evaluation period 21 days from the first dose administration Combination therapy - SRI. Number and proportion of patients with occurrence of dose reduction and discontinuation of study treatment due to TEAE from first dose of study treatment to 90 days after last dose of study treatment Monotherapy - Dose escalation and backfill cohorts. Number and proportion of patients with occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAE from first dose of study treatment to 90 days after last dose of study treatment Combination therapy - SRI. Number and proportion of patients with occurrence of Grade ≥ 3 abnormal safety laboratory parameters from first dose of study treatment to 90 days after last dose of study treatment Monotherapy - Dose escalation and backfill cohorts. Number and proportion of patients with occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by relationship from first dose of study treatment to 90 days after last dose of study treatment Combination therapy - SRI. Number and proportion of patients with occurrence of TEAEs including Grade ≥ 3, serious, fatal TEAE by relationship from first dose of study treatment to 90 days after last dose of study treatment Combination therapy - SRI. Occurrence of DLTs within a patient during the DLT evaluation period from first dose of study treatment to 90 days after last dose of study treatment Combination therapy - Expansion. Objective response rate (ORR) based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after the first dose of study treatment Reported with number and proportion of patients with a confirmed complete response (CR) or partial response (PR) as best overall response.
- Secondary Outcome Measures
Name Time Method Monotherapy - Dose escalation and backfill cohorts. Maximum concentration (Cmax) from pre-dose to the end of the dosing period from pre-dose to 21 days after study treatment for Cycle 1 and Cycle 2 Monotherapy - Dose escalation and backfill cohorts. Number and proportion of patients who developed detectable anti-drug antibody (ADA) from pre-dose to 90 days after last dose of study treatment Monotherapy - Dose escalation and backfill cohorts. Disease control rate (DCR) based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment Reported with number and proportion of patients with a CR, PR, or stable disease (SD) (assessed at least 6 weeks after first dose of study treatment) as best overall response.
Monotherapy - Dose escalation and backfill cohorts. Duration of response (DOR) based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression or death from any cause, whichever occurs first.
Combination therapy - Expansion. DOR based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression or death from any cause, whichever occurs first.
Combination therapy - SRI. ORR based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment Reported with number and proportion of patients with a confirmed CR or PR as best overall response.
Combination therapy - Expansion. PFS based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment Defined as time from first dose of study treatment to first confirmed disease progression or death from any cause, whichever occurs first.
Monotherapy - Dose escalation and backfill cohorts. Area under the concentration-time curve from pre-dose to last quantifiable time point prior to the next dose (AUClast) and from pre-dose to the end of the dosing period (AUCtau) from pre-dose to 21 days after study treatment for Cycle 1 and Cycle 2 Monotherapy - Dose escalation and backfill cohorts. ORR based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment Reported with number and proportion of patients with a confirmed CR or PR as best overall response.
Combination therapy - SRI. Progression-free survival (PFS) based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment Defined as time from first dose of study treatment to first confirmed disease progression or death from any cause, whichever occurs first.
Combination therapy - Expansion. Number and proportion of patients with occurrence of TEAEs including Grade ≥ 3, serious, fatal TEAE by relationship from first dose of study treatment to 90 days after last dose of study treatment Combination therapy - Expansion. Number and proportion of patients with occurrence of dose reduction and discontinuation of IMP due to TEAE from first dose of study treatment to 90 days after last dose of study treatment Combination therapy - Expansion. Number and proportion of patients with occurrence of Grade ≥ 3 abnormal safety laboratory parameters from first dose of study treatment to 90 days after last dose of study treatment Combination therapy - Expansion. Number and proportion of patients who developed detectable ADA from pre-dose to 90 days after last dose of study treatment Combination therapy - SRI. DCR based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment Reported with number and proportion of patients with a CR, PR, or SD (assessed at least 6 weeks after first dose of study treatment) as best overall response.
Combination therapy - SRI. DOR based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression or death from any cause, whichever occurs first.
Combination therapy - Expansion. AUClast and AUCtau from pre-dose to 21 days after study treatment for Cycle 1 Combination therapy - SRI. Overall survival (OS) up to 3 years after first dose of study treatment Defined as the time from first dose of study treatment to death from any cause.
Combination therapy - Expansion. DCR based on investigator's tumor assessment according to RECIST 1.1 up to 3 years after first dose of study treatment Reported with number and proportion of patients with a CR, PR, or SD (assessed at least 6 weeks after first dose of study treatment) as best overall response.
Combination therapy - Expansion. OS up to 3 years after first dose of study treatment Defined as the time from first dose of study treatment to death from any cause.
Combination therapy - Expansion. Cmax from pre-dose to the end of the dosing period from pre-dose to 21 days after study treatment for Cycle 1
Trial Locations
- Locations (14)
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
GZA Ziekenhuizen
🇧🇪Antwerpen, Belgium
CHU de Liège
🇧🇪Liege, Belgium
Rigshospitalet
🇩🇰Copenhagen, Denmark
START Midwest
🇺🇸Grand Rapids, Michigan, United States
Carolina BioOncology Institute, LLC
🇺🇸Huntersville, North Carolina, United States
National Cancer Center Hospital East
🇯🇵Kashiwanoha, Japan
Hospital Quironsalud Barcelona (NEXT Barcelona)
🇪🇸Barcelona, Spain
Hospital Fund. Jiménez Dia
🇪🇸Madrid, Spain
Clinica Universidad de Navarra
🇪🇸Pamplona, Spain
Royal Marsden Hospital - London
🇬🇧London, United Kingdom
Hospital HM Univ. Sanchinarro, Ensayos START
🇪🇸Madrid, Spain
Northern Centre for Cancer Care
🇬🇧Newcastle, United Kingdom
The Christie Hospital
🇬🇧Manchester, United Kingdom